NICHOLAS GOODWIN: Open Payments
NPI 1467948471 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,281 in 40 payments from 12 companies in 2025. Trend: 2023 $336 · 2024 $282 · 2025 $1,281
Food & beverage: $1,166Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $423 |
| Neurocrine BioSciences, Inc. | 4 | $156 |
| Alkermes, Inc. | 6 | $120 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Supernus Pharmaceuticals, Inc. | 3 | $115 |
| Axsome Therapeutics, Inc. | 4 | $108 |
| Lundbeck LLC | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
Products named: SPRAVATO, INVEGA SUSTENNA, REXULTI, Qelbree, Auvelity, LYBALVI, INGREZZA, COBENFY.
Industry payments across WA — which companies pay providers there.
